Multiple Sclerosis Therapeutics Market Growth Analysis

Market Insights

The Multiple Sclerosis Therapeutics Market was estimated to grow from USD 27.37 billion in 2021 to USD 42.53 billion by 2028 at a CAGR of around 6.50% during the forecast period.

Wish to get a free sample? Register Here

What is multiple sclerosis?

Multiple sclerosis (MS) is defined as an autoimmune disease that affects the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. The different types of drugs used to treat multiple sclerosis include immunomodulators, immunosuppressant, copaxone, avonex, gilenya and other.

Key Players

Key players operating in the Multiple Sclerosis Therapeutics market are-

• Novartis International AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi Genzyme (US)
• Bayer AG (Germany)
• Pfizer Inc. (US)
• Biogen Inc. (US)
• The Merck Group (Germany)
• AbbVie (US).

Market Dynamics

• The growth of the multiple sclerosis therapeutics markets is primarily driven by the rising number of people suffering from relapsing-remitting and secondary progressive multiple sclerosis.
• The increasing prevalence of chronic diseases due to changing lifestyle and stress are likely to drive market growth at a significant rate during the review period.
• the rising demand for novel drug development to treat multiple sclerosis is expected to create lucrative opportunities for the players operating in the market in the coming years.

COVID-19 Impact

The COVID-19 outbreak adversely affected the market growth of the multiple sclerosis therapeutics industries due to the shift of medical treatment to rising coronavirus-affected patients. Patients suffering from other diseases were asked to postpone their surgery/appointment due to a rapid surge in COVID-19 cases across the globe. 

To get the full scope of the report, Register Here

Segment Analysis

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The market is segmented into the following categories. 

By Drug Type 

• Immunomodulators
• Immunosuppressant
• Copaxone
• Avonex
• Gilenya
• Other

By Mode of Administration 

• Oral
• Injectable
• Intravenous

By Distribution Channel 

• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce

By Region

• North America
• APAC
• Europe 
• Rest of the World

Distribution Channel Trends

The market have been bifurcated into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period. The segment growth can be attributed to convenience and easy availability of required drugs at hospital pharmacies.

Regional Analysis

The North American market accounted for the largest market share in 2021 and is projected to grow at a robust CAGR during the review period. This can be attributed to the established presence of the healthcare industry coupled with the presence of key market players such as Sanofi Genzyme (US) and Pfizer Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people suffering from chronic diseases.

To know which region offers the best growth opportunities, Register Here

Target Audience

Here is the list of the group of customers that the multiple sclerosis therapeutics market hopes to have the greatest opportunity to convert-

• Distributors
• Suppliers
• Manufacturers
• Logistics organizations
• Government bodies

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What deliverables will you get in this report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Customization

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

Recent Developments

July 2022- Mymee, a leading provider of specialized care and support for people with significant symptoms associated with autoimmune disease and Long COVID, has acquired Berlin-based Breakthrough Health, the creator of the #1 mobile app Emilyn for people with multiple sclerosis (MS). With the acquisition, Mymee gains deeper expertise on the unique needs of MS patients and brings on Breakthrough Health’s experienced leadership to help scale Mymee’s personalized health platform and research. Read more…

July 2022- Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The company has partnered with Coastal Research Institute (CRI) to measure demyelination in patients with spinal cord stimulators using closed loop technology. Demyelination is a hallmark symptom of MS that occurs when the immune system attacks nerve fibers, causing lesions in the brain and spine.

June 2022- OM1, a leading real-world data, outcomes, and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by Sage Publications.